Bleselumab
Monoclonal antibody used in transplantation
Bleselumab is a monoclonal antibody that is being investigated for its potential use in preventing organ rejection in transplantation. It is a humanized antibody that targets the CD40 receptor, which plays a crucial role in the activation of the immune system.
Mechanism of Action[edit | edit source]
Bleselumab functions by binding to the CD40 receptor on B cells and other antigen-presenting cells. The CD40 receptor is involved in the activation and differentiation of B cells, as well as in the activation of T cells. By inhibiting the interaction between CD40 and its ligand, CD40L, bleselumab can suppress the immune response that leads to organ rejection. This makes it a promising candidate for use in immunosuppressive therapy following organ transplantation.
Clinical Development[edit | edit source]
Bleselumab is currently undergoing clinical trials to evaluate its safety and efficacy in preventing organ rejection. These trials are focused on patients who have received kidney transplants, as the drug aims to reduce the need for traditional immunosuppressive drugs, which can have significant side effects.
Potential Benefits[edit | edit source]
The use of bleselumab in transplantation could offer several benefits over existing therapies. By specifically targeting the CD40 pathway, it may provide a more targeted approach to immunosuppression, potentially reducing the risk of infection and other complications associated with broad-spectrum immunosuppressive drugs. Additionally, it may help in reducing the incidence of chronic rejection, a major cause of long-term graft loss.
Challenges and Considerations[edit | edit source]
While bleselumab shows promise, there are challenges that need to be addressed in its development. These include ensuring that the drug does not overly suppress the immune system, which could lead to increased susceptibility to infections and malignancies. Additionally, long-term studies are needed to fully understand the effects of CD40 inhibition on the immune system and overall patient health.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
